Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gersten, Todd L
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected	Active, not recruiting	3	358	Europe, Canada, US, RoW	Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)	Novartis Pharmaceuticals	Ovarian Cancer	04/23	06/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor	Completed	2	46	US	Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab	SCRI Development Innovations, LLC, Genentech, Inc.	Non-Small Cell Lung Cancer, Solid Tumor	08/24	08/24
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	2	83	US	efineptakin alfa, NT-I7, Atezolizumab, Tecentriq	NeoImmuneTech, Roche Pharma AG	Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer	09/24	03/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gersten, Todd L
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected	Active, not recruiting	3	358	Europe, Canada, US, RoW	Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)	Novartis Pharmaceuticals	Ovarian Cancer	04/23	06/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor	Completed	2	46	US	Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab	SCRI Development Innovations, LLC, Genentech, Inc.	Non-Small Cell Lung Cancer, Solid Tumor	08/24	08/24
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	2	83	US	efineptakin alfa, NT-I7, Atezolizumab, Tecentriq	NeoImmuneTech, Roche Pharma AG	Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer	09/24	03/25